Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york
4
×
new york blog main
new york top stories
4
×
alnylam pharmaceuticals
amgen
inclisiran
pcsk9 inhibitors
regeneron pharmaceuticals
abbvie
acorda therapeutics
akcea therapeutics
alirocumab
ampyra
anylam pharmaceuticals
apokyn
apomorphine
biotech
cardiomyopathy
cholesterol
dalfampridine
deals
drugs
duopa
evolocumab
fda
inbrija
inotersen
mylan
neuropathy
novartis
onpattro
parkinson's disease
patisiran
paul matteis
What
drug
fda
4
×
medicines
approved
cholesterol
disease
medco
new
patients
acorda
acquire
ago
agreed
akcea
alnylam
amyloidosis
attr
available
battle
billion
bringing
brings
cash
clears
closer
company
compound
cope
deal
debilitating
episodes
filing
friday
genetic
gets
help
inched
late
looms
lowering
Language
unset
Current search:
fda
×
" new york top stories "
×
" new york "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms